The benefit of surgery was most pronounced in men who were under age
65 when their tumor was diagnosed, a new, long-term Scandinavian
study found.
The results, published in The New England Journal of Medicine, don't
apply to prostate cancer detected during screening, such as with
blood tests to measure prostate specific antigen (PSA).
The study does, however, add new information to help guide treatment
of men with symptomatic or "incidentally" discovered prostate
cancer.
But the findings are complicated by the fact that treatment options
have changed since the study began in the 1990s.
Today, PSA testing often spots prostate tumors much earlier, and
patients have the option of so-called active surveillance, or
watchful waiting, wherein doctors closely monitor tumors and begin
treatment when the cancer seems to be getting aggressive. Typically,
prostate tumors grow so slowly that men will likely die from
something else before the cancer claims them.
Nonetheless, the results are "important because this is the longest
follow-up we have," said Dr. David Penson, chairman of urology at
Vanderbilt University Medical Center in Nashville, who wasn't
involved in the study. "It shows that if I have a long life
expectancy and if I have higher-grade disease, I probably need to
get some treatment because there's an advantage to surgery, and it's
not an insignificant advantage."
"If I'm an older, sicker guy with heart disease and my life
expectancy is less, maybe I don't have to have it treated," Penson
told Reuters Health in a telephone interview. "If I have low-grade
disease, maybe I don't need to be treated at all regardless of how
old I am."
"What we show is that radical prostatectomy can cure prostate cancer
but it's only for those who develop a lethal disease and who are
healthy enough to not die from something else," study leader Dr.
Anna Bill-Axelson of Uppsala University in Sweden told Reuters
Health by phone.
[to top of second column] |
Most people have low-risk disease, she said.
"Even in our study with advanced tumors, almost 70 percent of the
men died from other causes, so it shows you shouldn't treat
immediately, especially low- or intermediate-risk tumors," she said.
"You should wait and see if they get more aggressive and then treat
them."
The trial involved 695 men at 14 centers in Sweden, Finland and
Iceland.
During follow-up for an average of 23 years, there were 45 percent
fewer prostate cancer-related deaths in men who got radical surgery.
By 2017, 80 percent had died from any cause. Among men who had
immediate surgery, 72 percent died; among those who didn't, 84
percent died.
Prostate cancer accounted for 20 percent of deaths in the surgery
group and 31 percent of deaths in the watchful waiting cohort.
All volunteers were under age 75 at the start, with a life
expectancy of at least 10 years.
The cancer spread in 27 percent of the surgery group and in 43
percent of the watchful waiting group.
Radical prostatectomy produced the most benefit among men diagnosed
before age 65. Among these men, "overall mortality was 15 percentage
points lower, mortality due to prostate cancer was 15.1 percentage
points lower, and the risk of metastasis was 18.6 percentage points
lower in the radical-prostatectomy group than in the
watchful-waiting group," the researchers conclude.
SOURCE: https://bit.ly/2UrK62J The New England Journal of Medicine,
online December 12, 2018.
[© 2018 Thomson Reuters. All rights
reserved.] Copyright 2018 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |